Equillium (EQ) Convertible Debt (2017 - 2018)
Equillium (EQ) reported Convertible Debt of $10.3 million for Q3 2018, up 47.56% quarter-over-quarter from $7.0 million in Q4 2017.
Equillium (EQ) Convertible Debt (2017 - 2018) Analysis & Trends
Equillium (EQ) has 2 years of Convertible Debt data on file, last reported at $10.3 million in Q3 2018.
- Convertible Debt for Q3 2018 came in at $10.3 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2018 was $10.3 million (changed N/A YoY), and the FY2017 annual result was $7.0 million, changed N/A from the prior year.
- Convertible Debt rose to $10.3 million in Q3 2018 per EQ's latest filing, from $7.0 million in the prior quarter.
- Over five years, Convertible Debt peaked at $10.3 million in Q3 2018 and troughed at $7.0 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 10.32 Mn |
| Dec 31, 2017 | 6.99 Mn |